# A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older

> **NCT07311148** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Guangzhou Patronus Biotech Co., Ltd.** · enrollment: 840 (estimated)

## Conditions studied

- Herpes Zoster (HZ)
- Shingles
- VZV
- Recombinant Zoster Vaccine

## Interventions

- **BIOLOGICAL:** Low dose antigen and low dose adjuvant of LYB004
- **BIOLOGICAL:** Low dose antigen and high dose adjuvant of LYB004
- **BIOLOGICAL:** High dose antigen and low dose adjuvant of LYB004
- **BIOLOGICAL:** High dose antigen and high dose adjuvant of LYB004
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Positive control

## Key facts

- **NCT ID:** NCT07311148
- **Lead sponsor:** Guangzhou Patronus Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-10-23
- **Primary completion:** 2026-01
- **Final completion:** 2026-12
- **Target enrollment:** 840 (ESTIMATED)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07311148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07311148, "A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07311148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*